Jens C Eickhoff
Overview
Explore the profile of Jens C Eickhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
3434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lechuga C, Raza F, Colebank M, Korcarz C, Broman A, Eickhoff J, et al.
Chest
. 2025 Feb;
PMID: 40020994
Background: Pulmonary hypertension (PH) resulting from heart failure with preserved ejection fraction (PH-HFpEF) can lead to right ventricular-pulmonary arterial (RV-PA) uncoupling despite normal steady hemodynamics (eg, pulmonary vascular resistance). Unsteady...
2.
Uboha N, Basree M, Eickhoff J, Deming D, Matkowskyj K, Maloney J, et al.
J Surg Oncol
. 2025 Jan;
PMID: 39757733
Background And Objectives: Standard treatment of patients with stage II/III esophageal or gastroesophageal junction (E/GEJ) cancer involves neoadjuvant chemoradiation (nCRT), resection, and immunotherapy. Our trial evaluated the addition of perioperative...
3.
Using an in-office passive leg raise to identify older adults with suboptimal blood pressure control
Williams J, Cole M, Pewowaruk R, Hein A, Korcarz C, Raza F, et al.
J Hypertens
. 2024 Sep;
42(12):2155-2163.
PMID: 39248144
Introduction: Passive leg raise (PLR) is a simple, dynamic maneuver that has been used to increase preload to the heart. We hypothesize that PLR may offer a new and efficient...
4.
Coller R, DeMuri G, Eickhoff J, Singh-Verdeflor K, Warner G, Butteris S, et al.
J Sch Health
. 2024 Sep;
94(11):1009-1018.
PMID: 39228276
Background: Disparities in school attendance exist for children with medical complexity (CMC) due to COVID-19. Longitudinal changes in family-reported school safety perceptions and predictors of full-time, in-person school attendance are...
5.
Tonelli T, Eickhoff J, Johnson L, Liu G, McNeel D
Hum Vaccin Immunother
. 2024 Aug;
20(1):2395680.
PMID: 39208856
We have previously reported two single-agent phase I trials, evaluating the dose or schedule, of a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase (PAP) administered with GM-CSF as the adjuvant....
6.
Sharma K, Esbona K, Eickhoff J, Lloyd R, Hu R
Ann Diagn Pathol
. 2024 Jun;
73:152355.
PMID: 38878689
Long noncoding RNAs (lncRNAs) participate in transcriptional, epigenetic, and post-transcriptional regulation of gene expression and may influence carcinogenesis. MALAT1 is a lncRNA that is expressed in endocrine and many other...
7.
Sodji Q, Forsberg M, Cappabianca D, Kerr C, Sarko L, Shea A, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201618
Chimeric antigen receptor (CAR) T cells have been relatively ineffective against solid tumors. Low-dose radiation which can be delivered to multiple sites of metastases by targeted radionuclide therapy (TRT) can...
8.
McNeel D, Emamekhoo H, Eickhoff J, Kyriakopoulos C, Wargowski E, Tonelli T, et al.
J Immunother Cancer
. 2023 Dec;
11(12).
PMID: 38101860
Purpose: We have previously reported that a plasmid DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) had greater clinical activity when given in combination with pembrolizumab to patients with metastatic, castration-resistant...
9.
Bassetti M, Morris B, Sethakorn N, Lang J, Schehr J, Zhao S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Dec;
118(5):1481-1489.
PMID: 38072321
Purpose: Ablative local treatment of all radiographically detected metastatic sites in patients with oligometastatic non-small cell lung cancer (NSCLC) increases progression-free survival (PFS) and overall survival (OS). Prior studies demonstrated...
10.
Burton J, Johnston S, Vail D, Eickhoff J, Sykes K, Brown J, et al.
Vet Immunol Immunopathol
. 2023 Dec;
267:110691.
PMID: 38056066
Preventative anti-cancer vaccination strategies have long been hampered by the challenge of targeting the diverse array of potential tumor antigens, with successes to date limited to cancers with viral etiologies....